Skip to main content
ANAB
NASDAQ Life Sciences

AnaptysBio Reports Q2 2026 Net Income of $177.3M Driven by $181.5M Tax Benefit

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$55.99
Mkt Cap
$1.626B
52W Low
$13.658
52W High
$72.36
52W Position info
310% above low
Off High info
23% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ANAB has more than doubled off its 52-week low of $13.658.

Summary

AnaptysBio reported Q2 2026 net income of $177.3 million, driven by a $181.5 million non-cash tax benefit from the First Tracks spin-off. Jemperli royalties grew 34% year-over-year, and the GSK/Tesaro litigation judgment is expected in Q4 2026 or Q1 2027.


Key Events · Earnings and Guidance · ANAB

  • Q2 Net Income of $177.3M

    Net income from continuing operations was $177.3 million for the three months ended June 30, 2026, or $6.06 basic EPS, compared to $5.7 million in the prior-year quarter.

  • $181.5M Non-Cash Tax Benefit

    The income was driven by a $181.5 million benefit for income taxes from releasing a valuation allowance on deferred tax assets, tied to the April 2026 spin-off of First Tracks Biotherapeutics.

  • Jemperli Royalties Grow 34%

    Jemperli global net sales reached $644 million for the six months ended June 30, 2026, up 34% year-over-year, with collaboration revenue of $27.5 million for the quarter.

  • Cash Declines to $164.1M

    Cash, cash equivalents and investments totaled $164.1 million as of June 30, 2026, down $47.5 million from December 31, 2025, due primarily to $72.9 million in operating activities.


Analysis · ANAB · Life Sciences

A dramatic swing to profitability marks AnaptysBio's Q2 2026 results, with net income from continuing operations of $177.3 million for the quarter. This was driven almost entirely by a $181.5 million tax benefit from releasing a valuation allowance on deferred tax assets—a non-cash accounting event tied to the April 2026 spin-off of First Tracks Biotherapeutics, not operational performance. The company's core royalty business grew modestly: Jemperli global net sales rose 34% year-over-year to $644 million for the six months, and collaboration revenue increased to $27.5 million for the quarter. Cash declined to $164.1 million from $211.6 million at year-end, reflecting $72.9 million in operating cash burn. The litigation with GSK and Tesaro remains the key swing factor, with a post-trial hearing set for October 20, 2026 and a judgment expected in Q4 2026 or Q1 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANAB was trading at $55.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $13.66 to $72.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANAB - Latest Insights

ANAB
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $45.39 info
Change: -$2.38 (-5%) info
Market Cap: $1.349B info
ANAB
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $45.39 info
Change: -$2.38 (-5%) info
Market Cap: $1.349B info
ANAB
Oct 20, 2026, 3:49 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $45.00
Real-time Price: $45.39 info
Change: +$0.390 (+0.87%) info
Market Cap: $1.349B info
ANAB
Oct 19, 2026, 2:18 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $49.23
Real-time Price: $45.39 info
Change: -$3.84 (-8%) info
Market Cap: $1.349B info
ANAB
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $50.85
Real-time Price: $45.39 info
Change: -$5.46 (-11%) info
Market Cap: $1.349B info